Necrostatin-1 and necroptosis inhibition: Pathophysiology and therapeutic implications.
Pharmacol Res
; 163: 105297, 2021 01.
Article
in English
| MEDLINE | ID: covidwho-922113
ABSTRACT
Necrostatin-1 (Nec-1) is a RIP1-targeted inhibitor of necroptosis, a form of programmed cell death discovered and investigated in recent years. There are already many studies demonstrating the essential role of necroptosis in various diseases, including inflammatory diseases, cardiovascular diseases and neurological diseases. However, the potential of Nec-1 in diseases has not received much attention. Nec-1 is able to inhibit necroptosis signaling pathway and thus ameliorate necroptotic cell death in disease development. Recent research findings indicate that Nec-1 could be applied in several types of diseases to alleviate disease development or improve prognosis. Moreover, we predict that Nec-1 has the potential to protect against the complications of coronavirus disease 2019 (COVID-19). This review summarized the effect of Nec-1 in disease models and the underlying molecular mechanism, providing research evidence for its future application.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Necroptosis
/
SARS-CoV-2
/
COVID-19 Drug Treatment
/
Imidazoles
/
Indoles
/
Lung
/
Anti-Inflammatory Agents
Type of study:
Prognostic study
Limits:
Animals
/
Humans
Language:
English
Journal:
Pharmacol Res
Journal subject:
Pharmacology
Year:
2021
Document Type:
Article
Affiliation country:
J.phrs.2020.105297
Similar
MEDLINE
...
LILACS
LIS